[et_pb_section admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]
WHO releases second edition of consolidated ARV guidelines
The 2016 edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.
These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.
Dr Margaret Chan, director-general, World Health Organisation notes that “with this update of the consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, WHO, for the first time, recommends that all people living with HIV be provided with antiretroviral therapy (ART). This will bring us one step closer to achieving universal access to HIV treatment and care and ending Aids as a public health threat.
“These guidelines also make service delivery recommendations on how we can expand coverage of HIV treatment to reach the 37m people living with HIV. Key recommendations aim to improve the quality of HIV treatment and bring us closer to the universal health coverage ideals of integrated services, community-centred and community-led health care approaches, and shared responsibility for effective programme delivery.
“With its ‘treat-all’ recommendation, WHO removes all limitations on eligibility for ART among people living with HIV; all populations and age groups are now eligible for treatment, including pregnant women and children. The same once-per-day combination pill is now recommended for all adults living with HIV, including those with tuberculosis, hepatitis, and other co-infections. The guidelines are ambitious in their expected impact, and yet simplified in their approach, and firmly rooted in evidence. They take advantage of recent findings from clinical trials confirming that the early use of ART keeps people living with HIV alive and healthier and reduces the risk of transmitting the virus to their sexual and drug-sharing partners. Earlier treatment has the further advantage of simplifying the operational demands on programmes.
“Additional recommendations in the guidelines aim to help programmes deliver services closer to people’s homes; expedite reporting of test results; integrate HIV treatment more closely with antenatal, tuberculosis, drug dependence and other services; and use a wider range of health workers to administer treatment and follow-up care.
“If we are to achieve universal health coverage, we need to ensure that ART and broader HIV services reach those in greatest need and are sustainable in the long term. Integrating essential HIV services into national health benefit packages, promoting innovative public-private partnerships for increasing access to antiretroviral drugs and strengthening health and community systems to deliver comprehensive and quality services are key elements of an effective response.
“Countries have asked WHO to provide timely and practical guidance, guidance that keeps pace with the latest scientific evidence and enables services to be delivered equitably and sustainably to all populations in all countries. I believe these landmark guidelines go a long way towards meeting that request.
“The new guidelines support evidence-based interventions that can improve efficiency and effectiveness – so that more can be achieved with the resources at hand. At the same time, implementation of the guidelines will require increased investment from countries and shared responsibility. Implementing these guidelines fully will have an unprecedented impact on preventing people from becoming newly infected and reducing the number of people dying from HIV-related causes over the coming years – the number of people eligible for ART increases from 28m to all 37m people currently living with HIV globally.
“Expanding access to treatment is at the heart of a new treatment targets for 2020 with the aim of ending the Aids epidemic as a public health threat by 2030. The 90–90–90 targets include 90% of the people living with HIV know their HIV status, 90% of the people who know their HIV status receiving ART and 90% of the people receiving ART having suppressed viral loads.
“I am convinced that the future of the HIV response will follow the pattern of the recent past: that is, a constant willingness to build on past successes and rise to new challenges.
“This can fuel the momentum needed to push the HIV epidemic into an irreversible decline. I strongly encourage countries and their development partners to seize this unparalleled opportunity.”
[/et_pb_column][/et_pb_row][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]
WHO update to MDR-TB treatment guidelines
WHO treatment guidelines for drug-resistant tuberculosis (2016 update) contain policy recommendations on priority areas in the treatment of drug-resistant tuberculosis. The revision is in accordance with the WHO requirements for the formulation of evidence-informed policy.
The main novelties of the 2016 WHO guidelines are: a shorter MDR-TB treatment regimen is recommended under specific conditions; medicines used in the design of conventional MDR-TB treatment regimens are now reclassified to reflect updates in the evidence on their effectiveness and safety; specific recommendations are made on the treatment of children with rifampicin-resistant or MDR-TB based on a first-ever individual patient data meta-analysis; and recommendations on the role of surgery in MDR-TB case management are included.
[/et_pb_column][/et_pb_row][et_pb_row admin_label=”Row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Source” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]
[et_pb_cta admin_label=”Call To Action” title=”CONSULT WITH YOUR DOCTOR” button_url=”https://lab24.co.za” url_new_window=”off” button_text=”Contact LAB24 For Blood Tests” use_background_color=”on” background_color=”#ff0099″ background_layout=”dark” text_orientation=”center” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_button=”off” button_letter_spacing=”0″ button_use_icon=”default” button_icon_placement=”right” button_on_hover=”on” button_letter_spacing_hover=”0″]
It is important to seek professional medical advice from your doctor when dealing with HIV or TB related concerns.
A blood test can assist in diagnosis of infection and can also provide an accurate depiction of your general health status.